<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940202-2-00107</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=83 g=5 f=1 --> G. Other Prophylactic Measures  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> 1. Vaccination of Patients <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> Although pneumococci are not a major cause of nosocomial pneumonia, they have been identified as etiologic agents of serious nosocomial pulmonary infection and bacteremia.316&hyph;318 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  The following factors render patients at high risk of complications from pneumococcal infections: "65 years of age, chronic cardiovascular or pulmonary disease, diabetes mellitus, alcoholism, cirrhosis, cerebrospinal fluid leaks, immunosuppression, functional or anatomic asplenia, or HIV infection. Pneumococcal vaccine is effective in preventing pneumococcal disease. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 319,320 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Because two-thirds or more of patients with serious pneumococcal disease have been hospitalized at least once within 5 years before their pneumococcal illness, offering pneumococcal vaccine in hospitals, e.g., at the time of patient discharge, should contribute substantially to preventing the disease. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 319,321  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> 2. Prophylaxis With Systemic Antimicrobial Agents  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Systemic antimicrobial administration has been a prevalent practice in the prevention of nosocomial infections, including pneumonia, especially in patients who are weaned off mechanical ventilators, postoperative, and/or critically ill. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 322 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  However, the efficacy of such practice is questionable; and the potential for superinfection, which may result from any antimicrobial therapy, is a problem. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 84,322&hyph;326 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=5 f=1 --> 3. Kinetic Therapy for the Immobilized State  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> Continuous lateral rotational therapy (CLRT) or ``kinetic'' therapy is a recently introduced maneuver for prevention of pulmonary and other complications from prolonged immobilization or bed rest, such as in patients with acute stroke, critical illness, head injury or traction, blunt chest trauma, and/or mechanically assisted ventilation.327&hyph;332 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  CLRT involves the use of a bed that turns continuously and slowly (about eight full rotations per hour) along its longitudinal axis. Among the hypothesized benefits of CLRT are improved drainage of secretions within the lungs and lower airways, increased tidal volume, and reduction of venous thrombosis with resultant pulmonary embolization. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 174,333&hyph;335 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  However, the efficacy of CLRT in preventing pneumonia needs further evaluation because available studies yielded variable results. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 327&hyph;330 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  In addition, the studies either involved small numbers of patients, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 328 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  lacked adequate randomization, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 327 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  had no clear definition of pneumonia, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 327 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  did not distinguish between community-acquired and nosocomial pneumonia, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 328,332 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  or did not adjust for possible confounding factors such as mechanical ventilation, endotracheal intubation, nasogastric intubation, and enteral feeding. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 327  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=74 g=1 f=1 --> LEGIONNAIRES' DISEASE  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Legionnaires' disease is a multisystem illness, with pneumonia, caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Legionella spp.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In contrast, Pontiac fever is a self-limited influenza-like illness, without pneumonia, that is associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Legionella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 336 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> I. Epidemiology  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Since identification of the etiologic agent, numerous outbreaks of nosocomial Legionnaires' disease have been reported and have provided the opportunity to study the epidemiology of epidemic legionellosis. In contrast, the epidemiology of endemic Legionnaires' disease has not been well elucidated. The overall proportion of nosocomial pneumonias due to  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Legionella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp. in North America has not been determined, although individual hospitals have reported a ranges of 0%&hyph;14%. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 337&hyph;339 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Because diagnostic tests for  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Legionella spp.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> infection are not routinely performed on all patients with hospital-acquired pneumonia in most hospitals, this range probably underestimates the incidence of Legionnaires' disease. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Legionella  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> spp. are commonly found in a variety of natural and man-made aquatic environments <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 340,341 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and may enter hospital water systems in low or undetectable numbers. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 342,343 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Cooling towers, evaporative condensers, heated potable-water-distribution systems within hospitals, and locally produced distilled water can provide a suitable environment for legionellae to multiply. Factors known to enhance colonization and amplification of legionellae in man-made water environments include temperatures of 25&hyph;42 <!-- PJG 0017 degreeslatlong --> &cir;C, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 344&hyph;349 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  stagnation, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 350 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  scale and sediment, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 346 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and the presence of certain free-living aquatic amoebae that are capable of supporting intracellular growth of legionellae. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 351,352  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> A person's risk of acquiring legionellosis following exposure to contaminated water depends on a number of factors, including the type and intensity of exposure and the exposed person's health status. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 353&hyph;355 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Persons with severe immunosuppression or chronic underlying illnesses, such as hematologic malignancy or end-stage renal disease, are at markedly increased risk for legionellosis. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 355&hyph;358 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Persons in the later stages of acquired immunodeficiency syndrome are also probably at increased risk of legionellosis, but data are limited because of infrequent testing of patients. Persons with diabetes mellitus, chronic lung disease, or non-hematologic malignancy, those who smoke cigarettes, and the elderly are at moderately increased risk. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 336 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Nosocomial Legionnaires' disease has also been reported among patients at children's hospitals. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 359,360 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Underlying disease and advanced age are not only risk factors for acquiring Legionnaires' disease but also for dying from the illness. In a multivariate analysis of 3,524 cases reported to CDC from 1980 through 1989, immunosuppression, advanced age, end-stage renal disease, cancer, and nosocomial acquisition of disease were each independently associated with a fatal outcome. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 355 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  The mortality rate among 803 persons with nosocomially acquired cases was 40% compared with 20% among 2,721 persons with community-acquired cases, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> 355 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  probably reflecting increased severity of underlying disease in hospitalized patients.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            